Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Mucositis 3Hematologic Neoplasms 3Thrombocytopenia 1Sarcoma 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Multiple Myeloma 1Lymphopenia 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Graft vs Host Disease 1Cytopenia 1Chondrosarcoma 1Bone Neoplasms 1Anemia 1

Interventions

Gemcitabine 5Nivolumab 3Irinotecan 3Ipilimumab 3Docetaxel 3Cyclophosphamide 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3pegfilgrastim 2Vincristine 2Temozolomide 2Ibandronic Acid 2Everolimus 2Doxorubicin 2CTLA-4 Antigen 2spartalizumab 1saracatinib 1samarium Sm-153 lexidronam 1pembrolizumab 1palbociclib 1liposomal doxorubicin 1lenvatinib 1fludarabine 1anlotinib 1angiotensin I (1-7) 1aldesleukin 1Zoledronic Acid 1Trabectedin 1Topotecan 1Taxes 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Neoplasms × angiotensin I (1-7) × Clear all
NCT01553539 2018-07-05

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Wake Forest University Health Sciences

Phase 2 Completed
20 enrolled 10 charts
Sarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡